Evidence map›Paper›PMID 36678829›Full record

ArticlePharmaceutics2023

Identification of Nanoparticle Properties for Optimal Drug Delivery across a Physiological Cell Barrier.

Aisling M Ross, Rachel M Cahalane, Darragh R Walsh, Andreas M Grabrucker, Lynnette Marcar, John J E Mulvihill

Abstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aisling M RossBioScience and BioEngineering Research (BioSciBer), Bernal Biomaterials, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.ORCID 0000-0001-9139-3775
Rachel M CahalaneBioScience and BioEngineering Research (BioSciBer), Bernal Biomaterials, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.
Darragh R WalshBioScience and BioEngineering Research (BioSciBer), Bernal Biomaterials, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.
Andreas M GrabruckerBioScience and BioEngineering Research (BioSciBer), Bernal Biomaterials, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.ORCID 0000-0003-0005-4810
Lynnette MarcarDepartment of Applied Science, Technological University of the Shannon, V94 EC5T Limerick, Ireland.
John J E MulvihillBioScience and BioEngineering Research (BioSciBer), Bernal Biomaterials, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.

Funding

University of Limerick, Faculty of Science and Engineering 2016 - PhD student Scholarship
6 · The paper itself

Abstract

Nanoparticles (NPs) represent an attractive strategy to overcome difficulties associated with the delivery of therapeutics. Knowing the optimal properties of NPs to address these issues could allow for improved in vivo responses. This work investigated NPs prepared from 5 materials of 3 sizes and 3 concentrations applied to a cell barrier model. The NPs permeability across a cell barrier and their effects on cell barrier integrity and cell viability were evaluated. The properties of these NPs, as determined in water (traditional) vs. media (realistic), were compared to cell responses. It was found that for all cellular activities, NP properties determined in media was the best predictor of the cell response. Notably, ZnO NPs caused significant alterations to cell viability across all 3 cell lines tested. Importantly, we report that the zeta potential of NPs correlates significantly with NP permeability and NP-induced changes in cell viability. NPs with physiological-based zeta potential of -12 mV result in good cell barrier penetration without considerable changes in cell viability.

Indexed as

cell barriercharacterizationdisruptionnanocarrierspermeabilitytoxicity

Identifiers

PMID36678829
PMCPMC9865979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.